Luminice-203 yields its first topline data, but where are all the patients?

As the dust settles on ASCO the weekend’s immediate winners and losers emerge.

The end of three licensed assets sees Takeda take a step back from autologous cell therapy.

Five years after Affimed switched to NK cell engagers investors will see the fruits of a potentially registrational trial.

MorphoSys, Blueprint and Syndax celebrate a successful ASH; Cogent not so much.

Arcellx climbs 19%, but the most significant Car-T presentation at ASH might not even be in oncology.